Kanzo
Online ISSN : 1881-3593
Print ISSN : 0451-4203
ISSN-L : 0451-4203
Volume 56, Issue 12
Displaying 1-7 of 7 articles from this issue
Review Article
Case Reports
  • Hirofumi Tazawa, Saburo Fukuda, Seiji Fujisaki, Hideto Sakimoto, Takah ...
    2015 Volume 56 Issue 12 Pages 645-654
    Published: December 18, 2015
    Released on J-STAGE: January 08, 2016
    JOURNAL FREE ACCESS
    A 77-year-old man came for a detailed examination, because of chest pain during exercise. Cardiovascular CT revealed lung and liver tumor. PET-CT showed the focal FDG uptake in the lung tumor, whereas no accumulation in the liver. Lung lobectomy was performed and diagnose was Large cell neuroendocrine carcinoma. Three months after the cardiovascular CT, dynamic CT and MRI were performed for the liver, showed no change of tumor size and enhancement. There was not any tumor in the liver at CT performed 18 years ago. The tumor markers of HCC were markedly elevated with anti-HCV antibody-positive. Due to the above reasons, we suspected liver tumor to be HCC and, performed subsegmentectomy. The histological examination revealed a suggesting of spontaneous complete necrosis of HCC. This case is extremely rare because of two reasons. One is synchronous double cancer of HCC and lung cancer, and another is spontaneous complete necrosis of HCC.
    Download PDF (1268K)
  • Masashi Kono, Naoko Tsuji, Nobuto Ozaki, Nozomu Matsumoto, Takehisa Ta ...
    2015 Volume 56 Issue 12 Pages 655-660
    Published: December 18, 2015
    Released on J-STAGE: January 08, 2016
    JOURNAL FREE ACCESS
    A 51-year-old man with psoriasis vulgaris presented general malaise and liver dysfunction after 9 months of infliximab therapy. Viral blood tests (HBs antigen, anti-HBc antibody, anti-HCV antibody) were negative, while antimitochondrial M2 antibody titer was high, His autoantibody status before the therapy was unknown. His liver function normalized after stopping infliximab and starting the administration of ursodeoxycholic acid and bezafibrate. A liver biopsy specimen showed non-specific inflammatory change without chronic nonsuppurative destructive cholangitis. Several cases of infliximab-related hepatitis have been reported, and many of them were antinuclear antibody-positive, resembling autoimmune hepatitis. Only one case of primary biliary cirrhosis (PBC) after infliximab therapy has been reported, while a high ratio of PBC-psoriasis overlap was reported in England. Infliximab-immunomediated liver dysfunction is a novel disease group, and the further accumulation of cases is needed.
    Download PDF (661K)
  • Shinji Morii, Yoko Doi, Tomoo Makita, Shinichiro Takeda, Shuichi Saito ...
    2015 Volume 56 Issue 12 Pages 661-667
    Published: December 18, 2015
    Released on J-STAGE: January 08, 2016
    JOURNAL FREE ACCESS
    A 52-year-old female who was diagnosed with acute myeloid leukemia underwent allogeneic hematopoietic stem cells transplantation (allo-HSCT) in June 2009. She developed acute and chronic graft-versus-host disease after allo-HSCT, being monitored every half a year without requiring any therapy afterwards. In October 2014, she was admitted to our hospital because of showing elevated serum transaminase levels 1.5 months later after prescription of rosuvastatin for dyslipidemia. HBV serology showed hepatitis B surface antigen-positive and high IgM-hepatitis B core antibody titer, which raised the suspicion of acute hepatitis B. Her liver function improved to baseline values in one month without using the nucleoside analogue, confirming disappearance of serum HBV-DNA 2.5 months later. It was revealed that she had a history of resolved HBV infection prior to transplantation therapy. In conclusion she was diagnosed with de novo hepatitis B probably induced by rosuvastatin.
    Download PDF (460K)
  • Yusuke Watanabe, Toru Ishikawa, Satoshi Abe, Ryousuke Inoue, Tomoyuki ...
    2015 Volume 56 Issue 12 Pages 668-674
    Published: December 18, 2015
    Released on J-STAGE: January 08, 2016
    JOURNAL FREE ACCESS
    We herein report the case of a super-elderly patient with hepatic encephalopathy accompanied with chronic renal failure, who successfully underwent percutaneous transhepatic obliteration (PTO). An 85-year-old man was diagnosed with non-alcoholic fatty liver cirrhosis and chronic renal failure. He had a collateral vessel from the left portal vein to the paraesophageal vein, which caused repeated hepatic encephalopathy, and medications poorly controlled his hepatic encephalopathy. PTO was performed using a half dose of contrast medium. After PTO, his portal vein pressure did not increase; however, he had respiratory discomfort with right pleural effusion on the fifth day. The pleural effusion disappeared on increasing the diuretic dose. Although the diuretic dose was increased, his renal function did not worsen and the NH3 level did not increase. Hepatic encephalopathy might be controlled by performing PTO in a super-elderly patient, with minimal reduction in renal function from contrast medium and diuretics.
    Download PDF (684K)
Short Communication
Rapid Communication
feedback
Top